Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram once-per-week dose taken for 36 weeks.
This trial was done by injecting patients – which is how popular drugs Ozempic and Wegovy are administered – but it’s also being developed for oral administration.
It said most of the side effects were gastrointestinal and mild to moderate in severity.
Novo Nordisk said it is now planning further clinical development of amycretin in adults with overweight or obesity.
Novo Nordisk stock (DK:NOVO.B) (NVO) rallied 12% in Copenhagen trade, though it’s still down about 13% from where it was after a disappointing trial of CagriSema.
